Compare Salesforce Inc (CRM) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Johnson & Johnson — how do they compare? Salesforce Inc trades at $229.05 (market cap $187.48B), while Johnson & Johnson trades at $260.67 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 3.3× Salesforce Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Johnson & Johnson for 129 Days on average.
| CRM | JNJ | |
|---|---|---|
Market Cap | $187.48B | $618.09B |
Volume | 6,155,822 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $266.23 | $278.43 |
52-Week Low | $150.12 | $186.00 |
Typical Hold Time | 89 Days | 129 Days |
Enterprise Value | $217.82B | $646.37B |
Dividend Yield | 0.77% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $228.19, up 1.61% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 77.3% gross margins and 22% net income margin. Recent news highlights AI-driven growth potential despite sector-wide software stock volatility. Analyst consensus remains strongly bullish with a $271.91 price target, representing 19% upside potential from current levels.
CRM presents a compelling opportunity with strong profitability and AI monetization driving growth, though technical weakness and sector headwinds pose near-term risks. The company's rule of 44 performance and expanding free cash flow support long-term upside, but investors should monitor competitive pressures and macroeconomic conditions affecting software valuations.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
